- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT06087458
Phase 1/2 Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration (JOURNEY)
Fas 1/2a Doseskaleringsstudie av VOY-101 hos patienter med avancerad icke-neovaskulär åldersrelaterad makuladegeneration
The Phase 1 safety study of VOY-101 is comprised of escalating dose Cohorts, followed by a Phase 2 at the recommended phase 2 dose.
Studieöversikt
Status
Betingelser
Intervention / Behandling
Detaljerad beskrivning
The study has a prospective, open-label, multi-center, two-part design to evaluate a single, unilateral intravitreal (IVT) injection of VOY-101 in subjects with geographic atrophy (GA), the advanced form of non-neovascular age-related macular degeneration (AMD). Phase 1 followed a standard dose escalation model to establish safety and tolerability of VOY-101 and determine the recommended phase 2 dose. This dose is being used in the randomized Phase 2 part of the study to evaluate the safety and efficacy of VOY-101 in the study eye compared to untreated fellow eye.
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
- Fas 1
Kontakter och platser
Studieorter
-
-
New South Wales
-
Sydney, New South Wales, Australien, 2000
- Sydney Retina Clinic and Day Surgery
-
-
Victoria
-
East Melbourne, Victoria, Australien, 3002
- Cerulea Clinical Trials
-
-
-
-
Arizona
-
Scottsdale, Arizona, Förenta staterna, 85255
- Retina Macula Institute of AZ
-
-
California
-
Poway, California, Förenta staterna, 92064
- Retina Consultants San Diego
-
Sacramento, California, Förenta staterna, 95825
- Retinal Consultants Medical Group
-
-
Massachusetts
-
Boston, Massachusetts, Förenta staterna, 02114
- Ophthalmic Consultants of Boston
-
-
Missouri
-
St Louis, Missouri, Förenta staterna, 63128
- The Retina Institute
-
-
New Jersey
-
Cherry Hill, New Jersey, Förenta staterna, 08034
- Mid Atlantic Retina
-
-
Oregon
-
Portland, Oregon, Förenta staterna, 97221
- Retina Northwest
-
-
South Dakota
-
Rapid City, South Dakota, Förenta staterna, 57701
- Black Hills Regional Eye Institute
-
-
Texas
-
Austin, Texas, Förenta staterna, 78705
- Austin Research Center for Retina
-
Fort Worth, Texas, Förenta staterna, 76132
- Star Retina
-
Southlake, Texas, Förenta staterna, 76092
- Retina Center of Texas
-
-
Utah
-
Salt Lake City, Utah, Förenta staterna, 84132
- University of Utah John A. Moran Eye Center
-
-
-
-
-
Haifa, Israel
- Rambam Medical Center
-
Tel Aviv, Israel, 64239
- Tel-Aviv Sourasky Medical Center, Ophthalmology Division
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Are ≥60 years of age at the time of consent.
- Are willing and able to understand and provide written informed consent.
- Are willing and able to return for scheduled treatment and follow-up examinations.
- Are able to undergo ETDRS BCDVA testing and ophthalmic imaging.
- Well-demarcated GA secondary to AMD in the absence of MNV and in the absence of history of MNV for both eyes.
- Absence of signs of non-exudative MNV.
- Additional Ocular Inclusion Criteria for both eyes.
- Meet certain genotype criteria for risk of AMD.
Exclusion Criteria:
- Are women of childbearing potential (WOCBP) and are pregnant or unwilling to use and document use of effective contraception for the duration of the study.
- Additional Systemic, Ocular, and Genetic Exclusion Criteria.
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Randomiserad
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Enda
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Low
Single, unilateral, intravitreal injection of low dose of VOY-101 |
VOY-101 |
|
Experimentell: Medium
Single, unilateral, intravitreal injection of medium dose of VOY-101 |
VOY-101 |
|
Experimentell: High
Single, unilateral, intravitreal injection of high dose of VOY-101 |
VOY-101 |
|
Experimentell: Higher
Single, unilateral, intravitreal injection of higher dose of VOY-101 |
VOY-101 |
|
Experimentell: Intermediate
Single, unilateral, intravitreal injection of intermediate dose of VOY-101 |
VOY-101 |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Phase 1: To evaluate the safety and tolerability of a single intravitreal injection of escalating doses of VOY-101
Tidsram: 24 Months
|
Frequency and type of ocular and systemic adverse events and non-serious treatment-emergent adverse events |
24 Months
|
|
Phase 1: Change from Baseline in markers of inflammation
Tidsram: Baseline to Month 24
|
Change from Baseline in markers of inflammation including anterior chamber cells, vitreous cells, and retinal vasculitis and retinitis. |
Baseline to Month 24
|
|
Phase 1: Establish the recommended Phase 2 dose in subjects with Geographic Atrophy.
Tidsram: Month 12
|
Determine whether the maximum tolerated dose (MTD) has been reached (as determined by the occurrence of dose-limiting toxicities [DLTs]) and select the RP2D. |
Month 12
|
|
Phase 2: To evaluate the effect of VOY-101 in the study eye compared with untreated fellow eye on change in Geographic Atrophy lesion size.
Tidsram: 15 Months
|
Change from Baseline in Geographic Atrophy lesion size |
15 Months
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Phase 1: To evaluate the effect of VOY-101 on geographic atrophy lesion size and photoreceptors
Tidsram: Baseline through 24 Months
|
Growth rate of total geographic atrophy lesion size and photoreceptor change |
Baseline through 24 Months
|
|
Phase 1/2: To establish the pharmacokinetic (PK) profile of VOY-101.
Tidsram: Baseline through 24 Months
|
Change from Baseline for complement levels in aqueous humor |
Baseline through 24 Months
|
|
Phase 1/2: To evaluate the effect of VOY-101 on best corrected distance visual acuity
Tidsram: 24 Months
|
Change from Baseline in Early Treatment Diabetic Retinopathy Study (ETDRS) BCDVA and Percentage of subjects with <15 letters lost in BCDVA from Treatment |
24 Months
|
|
Phase 1/2: Development of macular neovascularization
Tidsram: Month 24
|
Incidence, frequency, severity, and timing of development of macular neovascularization |
Month 24
|
|
Phase 2: To further characterize the ocular and systemic safety and tolerability of VOY-101
Tidsram: 24 Months
|
Frequency of Investigational Product related ocular and systemic adverse events, adverse events of special interest and non-serious treatment-emergent adverse events. |
24 Months
|
|
Phase 2: To evaluate the effect of VOY-101 in the study eye compared with untreated fellow eye on geographic atrophy lesion size and photoreceptors
Tidsram: Baseline through Month 24
|
Change in geographic atrophy lesion size and rate of photoreceptor loss |
Baseline through Month 24
|
|
Phase 2: To evaluate the effect of VOY-101 on low luminance visual acuity
Tidsram: Baseline through Month 24
|
Change from Baseline in the change in visual function using Early Treatment Diabetic Retinopathy Study (ETDRS) Low Luminance Visual (LLVA) vision test |
Baseline through Month 24
|
Samarbetspartners och utredare
Sponsor
Utredare
- Studierektor: Anne Fung, MD, Perceive Biotherapeutics, Inc.
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- PBI-AMD-002
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .